[{"id":"b6dfc4a4-9444-4afb-ba81-847d531a5a05","acronym":"PIKHER2","url":"https://clinicaltrials.gov/study/NCT01589861","created_at":"2021-01-18T06:47:09.000Z","updated_at":"2024-07-02T16:37:24.069Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer","source_id_and_acronym":"NCT01589861 - PIKHER2","lead_sponsor":"Institut Paoli-Calmettes","biomarkers":" HER-2 • PIK3CA • PTEN","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation • PTEN mutation • AKT1 overexpression • PIK3CA expression • PIK3CA overexpression • PTEN negative","tags":["HER-2 • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation • PTEN mutation • AKT1 overexpression • PIK3CA expression • PIK3CA overexpression • PTEN negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • buparlisib (AN2025)"],"overall_status":"Suspended","enrollment":" Enrollment 106","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2017-03-28"}]